Zdrowie i gospodarka · 18/10/2023
FDA Clears Naropin Solutions for Continued Sale
The US Food and Drug Administration (FDA) has determined that Naropin (ropivacaine hydrochloride) solution, 50mg/10mL and 75mg/10mL, were not withdrawn from sale due to safety or effectiveness concerns, allowing the agency to continue approving abbreviated new drug applications (ANDAs) for these products.